I'm sorry, I'm not interested
loan instantly One person who does know: Narachi himself, who says he needs to know in order to make plans for his small company. Usually, CEOs are not privy to these data. That makes him the man who knows too much. He has to be careful not to tell investors any more about the study results than has been revealed so far ??? no new information about how Contrave is performing on heart disease or any other safety issue. Curious investors could be his biggest regulatory threat.